Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 32Neoplasms 19Neoplasm Metastasis 5Brain Neoplasms 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Sarcoma 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Multiple Myeloma 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Fever 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

trametinib 1dabrafenib 1Vincristine 1Irinotecan 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroma × dabrafenib × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡